GRAFT POLYMER UK LS -001 Total Liabilities
GRAFT POLYMER UK LS -001 total liabilities. Based on the latest financial reports, GRAFT POLYMER UK LS -001 (J4I) has total liabilities worth €1.39 Million EUR (≈ $1.63 Million USD) as of November 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See J4I defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of GRAFT POLYMER UK LS -001 (2022–2026)
Total liabilities of GRAFT POLYMER UK LS -001 from 2022 to 2026. This chart illustrates how GRAFT POLYMER UK LS -001's total liabilities have evolved over time, based on quarterly financial data.
GRAFT POLYMER UK LS -001 Competitors by Total Liabilities
The table below lists competitors of GRAFT POLYMER UK LS -001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PPHE Hotel Group Ltd
LSE:PPH
|
UK | GBX1.40 Billion |
|
Visgeneer
TWO:4197
|
Taiwan | NT$130.36 Million |
|
Celsius Resources Ltd
AU:CLA
|
Australia | AU$14.22 Million |
|
Nordic Flanges Group AB
ST:NFGAB
|
Sweden | Skr96.79 Million |
|
Millennium Silver Corp
V:MSC
|
Canada | CA$116.02K |
|
Lite Access Technologies Inc
V:LTE
|
Canada | CA$27.15 Million |
|
Dovre Group Plc
HE:DOV1V
|
Finland | €71.17 Million |
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
USA | $4.78 Million |
Liability Composition Analysis (2022–2026)
This chart breaks down GRAFT POLYMER UK LS -001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GRAFT POLYMER UK LS -001 (J4I) total assets.
Liquidity & Leverage Metrics
GRAFT POLYMER UK LS -001 Total Liabilities Ratios Explained
GRAFT POLYMER UK LS -001 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GRAFT POLYMER UK LS -001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GRAFT POLYMER UK LS -001 (2022–2026)
The table below shows the annual total liabilities of GRAFT POLYMER UK LS -001 from 2022 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-05-31 | €1.39 Million ≈ $1.63 Million |
+1071.43% |
| 2025-05-31 | €119.00K ≈ $139.12K |
-70.83% |
| 2024-05-31 | €408.00K ≈ $476.99K |
+5.97% |
| 2023-05-31 | €385.00K ≈ $450.11K |
-83.39% |
| 2022-05-31 | €2.32 Million ≈ $2.71 Million |
-- |
About GRAFT POLYMER UK LS -001
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre… Read more